These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 7907439)

  • 1. [Medico-economic evaluation. Good practices and methodology in the study of drugs].
    Lanoe JL; Flahaut MA; Legrain M
    Therapie; 1993; 48(4):303-6. PubMed ID: 7907439
    [No Abstract]   [Full Text] [Related]  

  • 2. Medico-economic evaluation of healthcare products. Methodology for defining a significant impact on French health insurance costs and selection of benchmarks for interpreting results.
    Dervaux B; Baseilhac E; Fagon JY; ; Biot C; Blachier C; Braun E; Debroucker F; Detournay B; Ferretti C; Granger M; Jouan-Flahault C; Lussier MD; Meyer A; Muller S; Pigeon M; De Sahb R; Sannié T; Sapède C; Vray M
    Therapie; 2014; 69(4):323-8. PubMed ID: 25230355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Analysis of the economic evaluation of drugs in primary care: concept, methodology and practical applications].
    Soto Alvarez J; Fernández Cano P
    Aten Primaria; 1997 Dec; 20(10):563-8. PubMed ID: 9494217
    [No Abstract]   [Full Text] [Related]  

  • 4. Dutch guidelines for economic evaluation: 'from good to better' in theory but further away from pharmaceuticals in practice?
    Garattini L; Padula A
    J R Soc Med; 2017 Mar; 110(3):98-103. PubMed ID: 28116955
    [No Abstract]   [Full Text] [Related]  

  • 5. [Introduction to pharmaco-economics: 'glossary'].
    Auray JP
    Therapie; 2001; 56(2):89-91. PubMed ID: 11471379
    [No Abstract]   [Full Text] [Related]  

  • 6. Could or Should We Use Cost-Effectiveness Thresholds in the French Value-Based Pricing Process for New Drugs?
    Ghabri S
    Pharmacoeconomics; 2024 Aug; 42(8):823-827. PubMed ID: 38733557
    [No Abstract]   [Full Text] [Related]  

  • 7. What is the budget impact of a new treatment or new health technology arriving on the market?
    Dervaux B; Le Fur C; Dubois S; Josseran A;
    Therapie; 2017 Feb; 72(1):93-103. PubMed ID: 28159198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic evaluation of pharmaceuticals: what are reasonable standards for clinical evidence--the Australian experience.
    Hill S; Henry D; Pekarsky B; Mitchell A
    Br J Clin Pharmacol; 1997 Nov; 44(5):421-5. PubMed ID: 9384457
    [No Abstract]   [Full Text] [Related]  

  • 9. [The use of modern economic methods for the rational choice of drugs].
    Khveshchuk PF; Rudakova AV; Galin AL
    Voen Med Zh; 1999 Aug; 320(8):54-9. PubMed ID: 10524003
    [No Abstract]   [Full Text] [Related]  

  • 10. [Haute Autorite de sante opinion on cost-effectiveness of health products : results and perspectives].
    Midy F; Raimond V; Thébaut C; Sambuc C; Rumeau-Pichon C
    Sante Publique; 2015; 27(5):691-700. PubMed ID: 26752035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NICE uses wrong comparator to assess cost effectiveness of new drugs, report says.
    Hawkes N
    BMJ; 2014 Mar; 348():g2134. PubMed ID: 24647344
    [No Abstract]   [Full Text] [Related]  

  • 12. [The cost of innovative drugs].
    Reggio S
    Recenti Prog Med; 1999; 90(7-8):371-2. PubMed ID: 10429514
    [No Abstract]   [Full Text] [Related]  

  • 13. Cost of preventive drugs. Dare to tell?
    Trewby PN
    BMJ; 2011 May; 342():d3198. PubMed ID: 21610062
    [No Abstract]   [Full Text] [Related]  

  • 14. US politicians want federal funding to discover cost effectiveness of new drugs.
    Moynihan R
    BMJ; 2003 Sep; 327(7416):642. PubMed ID: 14500428
    [No Abstract]   [Full Text] [Related]  

  • 15. [Evaluation of drug iatrogeny by medico-economic modelling techniques].
    Beresniak A; Taboulet F
    Therapie; 1997; 52(1):59-63. PubMed ID: 9183924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Dr Knock's return in reality: "Everyone is sick--but not everyone is aware about that!"].
    Melander A; Järhult B; Lindahl SO
    Lakartidningen; 2004 Jun; 101(23):2031. PubMed ID: 15232844
    [No Abstract]   [Full Text] [Related]  

  • 17. The economic value of companion diagnostics and stratified medicines.
    Blair ED; Stratton EK; Kaufmann M
    Expert Rev Mol Diagn; 2012 Nov; 12(8):791-4. PubMed ID: 23249194
    [No Abstract]   [Full Text] [Related]  

  • 18. [Important to keep the principle of value-based pricing of drugs].
    Persson U; Levin LA; Pettersson B
    Lakartidningen; 2009 Oct 28-Nov 3; 106(44):2862-4. PubMed ID: 19967967
    [No Abstract]   [Full Text] [Related]  

  • 19. New decision-making processes for the pricing of health technologies in Japan: The FY 2016/2017 pilot phase for the introduction of economic evaluations.
    Shiroiwa T; Fukuda T; Ikeda S; Takura T
    Health Policy; 2017 Aug; 121(8):836-841. PubMed ID: 28687183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Value-based pricing of drugs in the UK.
    Webb DJ; Walker A
    Lancet; 2007 Apr; 369(9571):1415-1416. PubMed ID: 17467498
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.